Inograft Biotherapeutics

Inograft Biotherapeutics develops targeted biologic conditioning therapies intended to make hematopoietic stem-cell transplantation safer and more precise. Its approach uses antibody-based, non-genotoxic conditioning to replace chemotherapy and radiation, which can damage healthy tissue and limit access to transplantation. The company uses research and predictive preclinical models to identify cellular and immune barriers to engraftment and advance therapies for blood and immune-system regeneration.